Does Q10 offer strength athletes cardiac protection?

Athletes who do strength sports develop an enlarged heart. This is not a problem in itself, but when combined with anabolic substances this enlargement can result in a fatal abnormality. Taking a Q10 co-enzyme supplement may offer protection, if the results of studies published by American cardiologists in the 1990s are anything to go by.

Heart enlargement
Under some conditions doing strength sports can cause an enlargement of the left ventricle in the heart. The muscles in this ventricle – in the septal wall and the posterior wall to be precise – that it leads to a reduction in the amount of blood that the ventricle can pump round the body.

Cardiologists observe this phenomenon primarily in people with high blood pressure, but occasionally chemical strength athletes also develop a dangerous form of left ventricular hypertrophy.

According to a 2003 Finnish study, it’s steroids users who also make long-term use of growth hormone that should be worried. [Int J Sports Med 2003; 24: 337-343.] The amount of blood that the heart is capable of pumping round the body can reach dangerously low levels in this group.

The American cardiologist Per Langsjoen has been publishing articles regularly since the 1980s on the cardiological effects of Q10. In the 1990s Langsjoen focused on people – not strength athletes – with an enlarged left ventricle. We dug up a small study that he did in 1997, in which he got seven patients to take an average of 200 mg Q10 every day for 3-48 months.

Does Q10 offer strength athletes cardiac protection?
Q10 [chemical formula shown here] is a molecular thumbtack, which functions as a distribution centre for electrons. If the cell pushes enough of these into the mitochondria membranes, they can generate energy faster and cells take longer to reach the point of exhaustion.

Left ventricular hypertrophy is believed to be caused by heart cells becoming chronically fatigued. Langsjoen reasoned that heart cell vitality could be restored through supplementation aimed at reducing the negative effects of left ventricular hypertrophy.

And hey presto: the table below shows that the subjects’ septal wall thickness [SWT] and the posterior wall thickness [PWT] decreased.



EF slope, LVEDD and FS are cardiological variables which indicate how well the heart is pumping blood. The results show an improvement, but it’s not statistically significant. Nevertheless, the patients had less chest pain, were less tired and less short of breath.

“These highly encouraging clinical and echocardiographic findings in hypertrophic cardiomyopathy are in keeping with the working hypothesis that CoQl0 has a beneficial effect on myocardial bioenergetics and ATP production”, the researchers conclude.

In 1999 Australian cardiologists published the results of a study which showed that Q10 supplementation had no effect on the left ventricle of patients. [J Am Coll Cardiol. 1999 May; 33(6): 1549-52.] They used a lower dose than the Americans.

Treatment of hypertrophic cardiomyopathy with coenzyme Q10.


Hypertrophic cardiomyopathy (HCM) is manifested by severe thickening of the left ventricle with significant diastolic dysfunction. Previous observations on the improvement in diastolic function and left ventricular wall thickness through the therapeutic administration of coenzyme Q10 (CoQ10) in patients with hypertensive heart disease prompted the investigation of its utility in HCM. Seven patients with HCM, six non-obstructive and one obstructive, were treated with an average of 200 mg/day of CoQ10 with mean treatment whole blood CoQ10 level of 2.9 micrograms/ml. Echocardiograms were obtained in all seven patients at baseline and again 3 or more months post-treatment. All patients noted improvement in symptoms of fatigue and dyspnea with no side effects noted. The mean interventricular septal thickness improved significantly from 1.51 +/- 0.17 cm to 1.14 +/- 0.13 cm, a 24% reduction (P < 0.002). The mean posterior wall thickness improved significantly from 1.37 +/- 0.13 cm to 1.01 +/- 0.15 cm, a 26% reduction (P < 0.005). Mitral valve inflow slope by pulsed wave Doppler (EF slope) showed a non-significant trend towards improvement, 1.55 +/- 0.49 m/sec2 to 2.58 +/- 1.18 m/sec2 (P < 0.08). The one patient with subaortic obstruction showed an improvement in resting pressure gradient after CoQ10 treatment (70 mmHg to 30 mmHg). PMID: 9266516 [PubMed - indexed for MEDLINE] Source: